The future of T-DM1 looks promising, especially as ongoing clinical trials are exploring its efficacy in other types of HER2-positive cancers and in combination with other therapies. Personalized medicine approaches and advancements in biomarker research may further enhance the effectiveness of T-DM1 and expand its use in cancer treatment.
